Verici Dx Plc (VRCI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verici Dx Plc (VRCI) has a cash flow conversion efficiency ratio of -1.091x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.71 Million ≈ $-329.35 USD) by net assets (GBX2.48 Million ≈ $301.99 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VRCI company net worth for the company's overall valuation and market capitalisation.
Verici Dx Plc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Verici Dx Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Verici Dx Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verici Dx Plc ranked by their cash flow conversion efficiency. See VRCI cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
London & Associated Properties
LSE:LAS
|
0.063x |
|
Presto Automation Inc.
NASDAQ:PRST
|
0.176x |
|
Empire Metals Limited
LSE:GEO
|
-0.066x |
|
PTT Exploration and Production Public Company Limited
F:PTTG
|
0.085x |
|
Unicorn Mineral Resources PLC
LSE:UMR
|
N/A |
|
Novae Group Plc
STU:NVAL
|
0.085x |
|
Argentex Group PLC
LSE:AGFX
|
0.094x |
|
ADVFN Plc
LSE:AFN
|
-0.094x |
Annual Cash Flow Conversion Efficiency for Verici Dx Plc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Verici Dx Plc from 2020 to 2024. View VRCI stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX5.26 Million ≈ $640.60 |
GBX-6.02 Million ≈ $-732.46 |
-1.143x | +43.18% |
| 2023-12-31 | GBX3.56 Million ≈ $432.91 |
GBX-7.16 Million ≈ $-871.16 |
-2.012x | -130.04% |
| 2022-12-31 | GBX11.51 Million ≈ $1.40K |
GBX-10.07 Million ≈ $-1.22K |
-0.875x | -65.46% |
| 2021-12-31 | GBX11.98 Million ≈ $1.46K |
GBX-6.34 Million ≈ $-770.96 |
-0.529x | -709.63% |
| 2020-12-31 | GBX19.62 Million ≈ $2.39K |
GBX-1.28 Million ≈ $-155.92 |
-0.065x | -- |
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more